Synthomer's stock price target has moved modestly, with analysts trimming their expectations from 112 GBp to 102 GBp. Despite this reduction, the fair value and risk profile remain steady. This suggests consensus that the company's core fundamentals are largely intact. Stay tuned to discover how you can keep informed as the narrative around Synthomer continues to evolve.

Analyst Price Targets don't always capture the full story. Head over to our Company Report to find new ways to value Synthomer.

Analyst perspectives on Synthomer have shifted following several recent price target adjustments by JPMorgan. These changes reflect evolving views on the company's near-term prospects and risk profile.

???? Bullish Takeaways

JPMorgan has consistently maintained a Neutral rating. This suggests that Synthomer’s core fundamentals and execution are regarded as stable in the eyes of the firm.

Analysts continue to acknowledge the company’s ability to manage costs and maintain operational transparency, even as valuation targets have been lowered.

???? Bearish Takeaways

JPMorgan recently reduced its price target for Synthomer from 200 GBp to 112 GBp, and subsequently to 102 GBp. These changes signal a more cautious stance on future growth and valuation.

The firm’s maintained Neutral rating, together with lower price targets, indicates reservations about the company’s near-term upside potential and possible exposure to sector risks.

Overall, recent analyst commentary from JPMorgan suggests a balanced view, with continued acknowledgment of management’s core strengths, but heightened caution regarding valuation and immediate growth prospects.

Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives or begin writing your own Narrative!

Synthomer plc has issued earnings guidance for 2026, indicating expectations for improved Group earnings and stronger cash generation. This outlook is supported by anticipated benefits from ongoing self-help initiatives and recent product investments.

Synthomer has announced a new partnership with Lummus Technology to license its proprietary acrylic acid esters technology. The collaboration is designed to enable flexible and robust production solutions, using a variety of raw materials, including bio-based feedstocks.

Recent developments highlight Synthomer's continued focus on operational improvements and strategic collaborations, reflecting management's commitment to both innovation and sustainability in its core business areas.

Fair Value remains unchanged at £1.34, indicating analysts see no shift in intrinsic valuation.

Discount Rate is steady at 13.19 percent, reflecting a consistent perspective on risk premiums required for the company.

Revenue Growth projection is virtually flat and holds at 1.86 percent. This suggests that expectations for top-line expansion are consistent with prior forecasts.

Net Profit Margin has risen significantly from 7.37 percent to 10.09 percent. This shows improved profitability estimates for future periods.

Future P/E ratio has fallen from 2.15x to 1.57x. This points to lower expected earnings multiples, which may indicate a more cautious outlook for future growth or higher forecasted earnings.

A "Narrative" is a powerful tool that brings a company's story together with the numbers behind it. It connects what’s happening in Synthomer’s business to forecasts for its future revenue, earnings, and fair value. Narratives on Simply Wall St, used by millions of investors, make it easy to compare fair value to market price and are always kept current as news or results change. This can help you decide when to buy or sell.

Head over to the original Synthomer Narrative to discover:

Why Synthomer's strategic shift to specialty polymers and cost reduction could drive margin recovery and long-term growth.

How innovations in eco-friendly products position the company to benefit from major sustainability trends and regulatory changes.

What key risks, such as high leverage and exposure to slow-growing markets, could limit Synthomer’s ability to fully capitalize on its turnaround.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include SYNT.L.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com